Nasdaq

Toripalimab data will also be featured in ASCO’s official press program

Publication: June 3, 2021, 5:00 p.m. Eastern Daylight Time “We are excited that results of JUPITER-02, a Phase 3 clinical trial evaluating toripalimab plus chemotherapy for the first-line treatment of ...
Yahoo Finance

Coherus and Junshi Biosciences Announce Toripalimab in Combination with Chemotherapy Met Primary Progression Free Survival (PFS) Endpoint as First Line Treatment for Recurrent ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Financial Times

Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Advanced TNBC

SHANGHAI, June 25, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the ...
Financial Times

Junshi Biosciences Announces Toripalimab plus Chemotherapy Significantly Improved Event-free Survival (EFS) versus Chemotherapy as Perioperative Treatment for Resectable Stage ...

Perioperative toripalimab plus chemotherapy significantly improved EFS and reduced risk of disease recurrence, progression events or death by 60% among resectable stage III NSCLC patients, compared to ...
Seeking Alpha

Junshi's toripalimab gets Chinese regulator review for expanded use in breast cancer

Shanghai Junshi Biosciences (OTCPK:SHJBF) said China's National Medical Products Administration (NMPA) accepted an application seeking expanded approval of toripalimab, in combination with ...
ascopubs.org

Toripalimab in patients with previously treated advanced upper tract urothelial carcinoma: A subgroup analysis of the phase II POLARIS-03 trial.

Effect of loss of KDM6A-mediated genomic instability and metabolic reprogramming on response to therapeutic perturbations in bladder cancer. Efficacy outcomes by PD-L1 and TMB subgroups in patients ...
Medscape

New Drug Toripalimab Improves Survival in Nasopharyngeal Cancer

A new immunotherapy, toripalimab, has the potential to change practice in the treatment of nasopharyngeal carcinoma (NPC), say experts. The drug is a monoclonal antibody that blocks programmed cell ...
Nasdaq

Coherus Announces Toripalimab Achieved Primary Endpoints of Progression Free Survival and Overall Survival in Interim Analysis of Phase 3 Clinical Trial in First-Line ...

REDWOOD CITY, Calif., April 23, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS) has received notice from immuno-oncology partner Junshi Biosciences that the Independent Data ...
Medscape

FDA Approves Toripalimab for Nasopharyngeal Carcinoma

The US Food and Drug Administration (FDA) has approved toripalimab-tpzi (Loqtorz, Coherus BioSciences) in combination with cisplatin and gemcitabine for the first-line treatment of adults with ...
PE Hub

SK Capital’s Apotex to acquire Canadian rights to Toripalimab

SK Capital Partners portfolio company Apotex has agreed to acquire the license to the Canadian rights to Toripalimab, an anti-PD-1 monoclonal antibody, from Coherus Biosciences. No financial terms of ...
Benzinga.com

Coherus and Junshi Biosciences Receive CRL from FDA for Toripalimab in combination with Gemcitabine and Cisplatin In metastatic nasopharyngeal carcinoma (NPC)

Shanghai Junshi Biosciences and Coherus BioSciences, Inc. CHRS received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) ...